BioSpace News Archive

AcuityMD , a platform for commercializing and improving medical devices with data, announced today the close of a $7 million financing round led by Benchmark with participation from Ajax Health. Eric Vishria, General Partner at Benchmark will also join AcuityMD’s board of directors.

Appointment is Effective May 24, 2021 Mr. Velis will continue his role on Noveome’s Board of Directors William J. Golden steps down as CEO, remains as Founder and Chairman of the Board of Directors

Aspekt Solutions , a leading provider of radiation oncology and radiology solutions, is pleased to announce the acquisition of Nordic Medical Physics. This strategic acquisition increases the consulting capabilities and expands the geographic footprint of Aspekt Solutions.

The CEO Roundtable on Cancer has elected Scott White , Company Group Chairman for North America at the Janssen Pharmaceutical Companies of Johnson & Johnson, to its Board of Directors.

Bioclinica, an ERT company, today announced receiving 2021 CRO Leadership Awards for four consecutive years in multiple performance categories.

Signati Medical, Inc., a medical device company focused on advancing men’s health with a proprietary bipolar radio frequency sealing platform, announced today that the company initiated a second preclinical study on New Zealand rabbits.

Prytime Medical Devices, Inc. announced today it has received both UK and CE Mark Approval for its next-generation ER-REBOA PLUS™ Catheter. Designed for improved ease of use, this catheter replaces the market defining ER-REBOA™ catheter and represents an important evolution of REBOA technology.

X-Pure® GelDAT, combines purity with superior adhesion performance to increase the potential of in-body applications reaching the clinic.

FedRAMP certification enables federal agencies, or federally funded projects, to engage more deeply with the cloud computing system for handling sensitive data.

Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (“Brooklyn” ) , a biopharmaceutical company currently focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer and blood disorders, today announced it has completed a $20M financing to progress the development of the mRNA gene editing and cell therapies technology recently licensed from Factor Biosciences